Is a malaria vaccine a wise investment for countries and international partners?
Countries with malaria face a wide range of challenges. One significant challenge is constructing the optimal menu of interventions to deal with their critical public health problems.
MVI is undertaking a comprehensive scope of economic analyses at the country level. We are working with economists and social scientists in seven African countries as well as other partners to conduct comprehensive economic analyses to inform use of malaria vaccines. The analyses build on other economic work, including that related to intermittent presumptive treatment in infants (IPTI). (Read more on the website of the IPTI Consortium.)
Through our economic work, we will ensure that countries have robust, credible country-level data to answer the following questions:
- Is the vaccine cost effective?
- Does it make sense for us to include this vaccine in our Expanded Program on Immunization (EPI) schedule, given the evidence on potential benefits and costs, its cost effectiveness in relation to other available malarial control options, and the competing demands on available resources?
- Are there possible net savings to the health system as a result of this vaccine, or should we expect additional costs over current EPI expenditure?
- If the latter, what are the budgetary implications for us?
- Will the vaccine be both affordable and sustainable?
- What would be the likely impact on the existing EPI program, and what adjustments might this entail?
Through our economic work with partners and countries, we will also ensure that there is economic data to understand the following:
- The cost-effectiveness of a new vaccine.
- The budgetary impact of malaria vaccines in a range of countries.
- Costs of introduction and relationship to other malarial interventions.